Lipoxin A4 activates Nrf2 expression and mitigates hyperglycaemia-induced impairment of myogenesis and rescues damage to mitochondria
Journal of Physiology and Biochemistry · 2026-12 · 82 (1)
DOI: 10.1007/s13105-026-01166-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Physiology and Biochemistry, online erschienen am 02.03.2026. Verfasst von Akash Mitra und 6 weiteren Autor:innen. Beteiligte Einrichtung: Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangalore, 5…. Hauptthemen laut MEDLINE: Lipoxins, NF-E2-Related Factor 2, Muscle Development, Hyperglycemia. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India.
Abstract (Originalsprache)
High glucose toxicity or hyperglycaemia manifests through various downstream processes, one of which is the elevation of oxidative stress. One of the consequences of increased reactive oxygen species production is mitochondrial damage, both metabolically and structurally. Arachidonic acid (AA) has been shown to salvage mitochondrial dysfunction in skeletal muscles. In this study, we explore the effects of lipoxin A4 (LXA4), a downstream anti-inflammatory metabolite of arachidonic acid, on mitigating hyperglycaemia-induced oxidative stress at the molecular level. We observed that LXA4 could substantially inhibit ROS production and restore Nrf2 expression (by 14%). Additionally, lipoxin A4 treatment was able to restore the mitochondrial potential and prevent mitochondrial fragmentation. Finally, due to the rescue of mitochondrial homeostasis and energetics, the process of myogenesis, an energy-extensive phenomenon, was also restored by the lipid treatment as evident from the differentiation parameters like myotube diameter and myonuclei fusion index, and the expression of MyoD, which drives the transition of myoblasts from proliferation to differentiation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangalore, 575018, Karnataka, India.
- UND Life Sciences, 2221 NW 5th St, WA, Battle Ground, 98604, USA.
- Department of Biotechnology, Indian Institute of Technology-Hyderabad, Kandi Village, Sangareddy Mandal, Telangana, India.
- Department of Medicine, Omega Hospitals, Gachibowli, Hyderabad, 500032, India.
- Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre, Yenepoya (Deemed to be University), University Road, Deralakatte, Mangalore, 575018, Karnataka, India. bipasha.bose@yenepoya.edu.in.
- Specialized Research Centre, Yenepoya Medical College, Yenepoya (Deemed to be University), Deralakatte, Mangalore, 575018, Karnataka, India. bipasha.bose@yenepoya.edu.in.
Förderung
- Department of Biotechnology, Ministry of Science and Technology, India
Zitieren
APA
Mitra, A., Bhat K, D., Pinto, J. R., Mandal, S., Das, U. N., Bose, B., & Shenoy P, S. (2026). Lipoxin A4 activates Nrf2 expression and mitigates hyperglycaemia-induced impairment of myogenesis and rescues damage to mitochondria. Journal of Physiology and Biochemistry, 82(1). https://doi.org/10.1007/s13105-026-01166-2
Vancouver
Mitra A, Bhat K D, Pinto JR, Mandal S, Das UN, Bose B, et al. Lipoxin A4 activates Nrf2 expression and mitigates hyperglycaemia-induced impairment of myogenesis and rescues damage to mitochondria. Journal of Physiology and Biochemistry. 2026;82(1). doi:10.1007/s13105-026-01166-2
BibTeX
@article{Mitra2026,
author = {Mitra, Akash and Bhat K, Deepika and Pinto, Joel Rimson and Mandal, Samanwita and Das, Undurti Narasimha and Bose, Bipasha and Shenoy P, Sudheer},
title = {Lipoxin A4 activates Nrf2 expression and mitigates hyperglycaemia-induced impairment of myogenesis and rescues damage to mitochondria},
journal = {Journal of Physiology and Biochemistry},
year = {2026},
volume = {82},
number = {1},
doi = {10.1007/s13105-026-01166-2}
}
EUVIMED